EP2207669A4 - Bakteriostatische oder bakteriozide zusammensetzungen und verfahren - Google Patents

Bakteriostatische oder bakteriozide zusammensetzungen und verfahren

Info

Publication number
EP2207669A4
EP2207669A4 EP08842668A EP08842668A EP2207669A4 EP 2207669 A4 EP2207669 A4 EP 2207669A4 EP 08842668 A EP08842668 A EP 08842668A EP 08842668 A EP08842668 A EP 08842668A EP 2207669 A4 EP2207669 A4 EP 2207669A4
Authority
EP
European Patent Office
Prior art keywords
bacteriostatic
methods
bacteriocidal compositions
bacteriocidal
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08842668A
Other languages
English (en)
French (fr)
Other versions
EP2207669A1 (de
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2207669A1 publication Critical patent/EP2207669A1/de
Publication of EP2207669A4 publication Critical patent/EP2207669A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP08842668A 2007-10-25 2008-10-23 Bakteriostatische oder bakteriozide zusammensetzungen und verfahren Withdrawn EP2207669A4 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US98272007P 2007-10-25 2007-10-25
US98271907P 2007-10-25 2007-10-25
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US4840408P 2008-04-28 2008-04-28
US4841608P 2008-04-28 2008-04-28
US4834008P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
PCT/US2008/081029 WO2009055620A1 (en) 2007-10-25 2008-10-23 Bacteriostatic or bacteriocidal compositions and methods

Publications (2)

Publication Number Publication Date
EP2207669A1 EP2207669A1 (de) 2010-07-21
EP2207669A4 true EP2207669A4 (de) 2011-11-02

Family

ID=42238385

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08842668A Withdrawn EP2207669A4 (de) 2007-10-25 2008-10-23 Bakteriostatische oder bakteriozide zusammensetzungen und verfahren
EP08841984.1A Not-in-force EP2214712B1 (de) 2007-10-25 2008-10-27 Zusammensetzungen und verfahren zur behandlung von asthma und lungenerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08841984.1A Not-in-force EP2214712B1 (de) 2007-10-25 2008-10-27 Zusammensetzungen und verfahren zur behandlung von asthma und lungenerkrankungen

Country Status (8)

Country Link
EP (2) EP2207669A4 (de)
JP (3) JP5586470B2 (de)
CN (3) CN101909869B (de)
AU (2) AU2008316708A1 (de)
CA (2) CA2703648A1 (de)
IL (2) IL205321A0 (de)
MX (1) MX2010004549A (de)
WO (1) WO2009055620A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2086668B1 (de) 2006-10-25 2016-11-16 Revalesio Corporation Mischvorrichtung und verfahren
EP2207669A4 (de) * 2007-10-25 2011-11-02 Revalesio Corp Bakteriostatische oder bakteriozide zusammensetzungen und verfahren
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
JP5613565B2 (ja) * 2007-10-25 2014-10-22 リバルシオ コーポレイション 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
BRPI0911757A2 (pt) 2008-05-01 2013-09-17 Revalesio Corp composiÇÕes e mÉtodos para tratar distérbios digestivos.
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
BR112012028540A2 (pt) 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2726016B1 (de) 2011-06-28 2023-07-19 ForSight Vision4, Inc. Vorrichtung zum sammeln einer flüssigkeitsprobe aus einer reservoirkammer einer therapeutischen vorrichtung für das auge
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
KR101930573B1 (ko) * 2014-04-23 2018-12-18 주식회사 티씨엠생명과학 세포 도말 장치 및 세포 도말 방법
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP7037360B2 (ja) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド 拡張可能な薬物送達デバイス
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
CN109788979B (zh) * 2016-06-27 2022-04-19 盖能适治疗股份有限公司 发生器和具有电极的导管以及用于治疗肺通道的方法
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
EP3737475A4 (de) 2018-02-16 2021-03-24 University Of Louisville Research Foundation, Inc. Atemtrainings- und atemwegdrucküberwachungsgerät
KR102171489B1 (ko) * 2018-10-30 2020-10-29 (주)메가메디칼 네블라이저 및 산소공급기가 구비되는 네블라이저 장치
CN115666546A (zh) * 2020-04-03 2023-01-31 卢普奥克西治疗公司 肠内有氧化疗法
EP4144353A4 (de) * 2020-04-30 2024-08-28 FUJIFILM Toyama Chemical Co., Ltd. Coronavirus-infektionstherapeutikum aus einer kombination aus einem pyrazinderivat und einem anderen coronavirus-infektionstherapeutikum
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083610A1 (en) * 2001-02-01 2003-05-01 Mcgrath Terrence S. Compositions and method of tissue superoxygenation
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157720A (ja) * 1996-11-07 1999-03-02 Honda Motor Co Ltd 電解機能水、その製造方法及び製造装置
IL124788A (en) * 1998-06-07 1999-04-11 Ben Hador David Boomerang launcher
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
CA2388934A1 (en) * 1999-10-26 2001-05-03 Bio-Hydration Research Lab, Inc. Micro-cluster liquids and methods of making and using them
US6426066B1 (en) * 2000-01-12 2002-07-30 California Pacific Labs, Inc. Use of physiologically balanced, ionized, acidic solution in wound healing
ATE293962T1 (de) * 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
US20030199089A1 (en) * 2001-06-05 2003-10-23 Surber Mark W. Membrane to membrane delivery
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
JP4144669B2 (ja) * 2004-03-05 2008-09-03 独立行政法人産業技術総合研究所 ナノバブルの製造方法
CA2574848A1 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
US8697120B2 (en) * 2006-05-01 2014-04-15 Johns Hopkins University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2008115290A2 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Methods of wound care and treatment
JP5613565B2 (ja) * 2007-10-25 2014-10-22 リバルシオ コーポレイション 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法
EP2207669A4 (de) * 2007-10-25 2011-11-02 Revalesio Corp Bakteriostatische oder bakteriozide zusammensetzungen und verfahren
JP2011050844A (ja) * 2009-09-01 2011-03-17 Kurita Water Ind Ltd 電気浸透脱水方法及び装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
US20030083610A1 (en) * 2001-02-01 2003-05-01 Mcgrath Terrence S. Compositions and method of tissue superoxygenation
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KHUSHBU K. MODI ET AL: "A Physically-Modified Saline Suppresses Neuronal Apoptosis, Attenuates Tau Phosphorylation and Protects Memory in an Animal Model of Alzheimer's Disease", PLOS ONE, vol. 9, no. 8, 4 August 2014 (2014-08-04), pages e103606, XP055163418, DOI: 10.1371/journal.pone.0103606 *
S. KHASNAVIS ET AL: "Suppression of Nuclear Factor- B Activation and Inflammation in Microglia by Physically Modified Saline", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 35, 24 August 2012 (2012-08-24), pages 29529 - 29542, XP055062907, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.338012 *
SAURABH KHASNAVIS ET AL: "Protection of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease by a Physically-Modified Saline Containing Charge-Stabilized Nanobubbles", JOURNAL OF NEUROIMMUNE PHARMACOLOGY, vol. 9, no. 2, 11 October 2013 (2013-10-11), pages 218 - 232, XP055164426, ISSN: 1557-1890, DOI: 10.1007/s11481-013-9503-3 *
See also references of WO2009055620A1 *

Also Published As

Publication number Publication date
JP5647897B2 (ja) 2015-01-07
CN103721258A (zh) 2014-04-16
CN101909649A (zh) 2010-12-08
JP2011500854A (ja) 2011-01-06
CN101909869A (zh) 2010-12-08
CN103721258B (zh) 2015-12-09
EP2214712A4 (de) 2013-02-27
IL205321A0 (en) 2010-12-30
CA2703648A1 (en) 2009-04-30
AU2008316556A1 (en) 2009-04-30
CN101909649B (zh) 2014-01-29
AU2008316708A1 (en) 2009-04-30
WO2009055620A1 (en) 2009-04-30
MX2010004549A (es) 2010-07-28
IL205320A0 (en) 2010-12-30
JP2015028087A (ja) 2015-02-12
EP2214712B1 (de) 2016-05-18
EP2214712A1 (de) 2010-08-11
JP5750540B2 (ja) 2015-07-22
EP2207669A1 (de) 2010-07-21
CN101909869B (zh) 2014-12-17
JP5586470B2 (ja) 2014-09-10
AU2008316556B2 (en) 2014-12-18
JP2011500838A (ja) 2011-01-06
IL205320A (en) 2017-03-30
CA2703714A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EP2349019A4 (de) Abschlussvorrichtungen und entsprechende verfahren
BRPI0819573A2 (pt) Composição e artigo
EP2086318A4 (de) Neuroprotektive zusammensetzungen und verfahren
EP2266677A4 (de) Luftreiniger
EP2178591A4 (de) Tracheostomaventile und entsprechende verfahren
DE602007011880D1 (de) Partikelmischgerät
BRPI0716300A2 (pt) Artigo e mistura
ATE526567T1 (de) Zusammensteller und zusammenstellungsverfahren
EP2280916A4 (de) Hydrochlorfluorolefinzusammensetzungen
BRPI0913806A2 (pt) "composição"
EP2488029A4 (de) Verfahren und zusammensetzungen zur abschreckung vor missbrauch
BRPI0716325A2 (pt) Composição antimicrobianas
EP2490720A4 (de) Anti-gcc-antikörpermoleküle sowie entsprechende zusammensetzungen und verfahren
BRPI0812214A2 (pt) purificador desinfetante de efeito prolongado
EP2314945A4 (de) Klimaanlage
BRPI0716881A2 (pt) Composições tópicas
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
EP2341297A4 (de) Klimaanlage
EP2326704A4 (de) Granulare reinigungs- und desinfektionszusammensetzung
EP2287836A4 (de) Encoder, decoder und verfahren dafür
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
BRPI0815987A2 (pt) "artigo absorbente"
BRPI1007667A2 (pt) condicionador capilar e composição
EP2043136A4 (de) Filmbildungszusammensetzung
BRPI0918328B8 (pt) composição e artigo

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111006

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20110929BHEP

Ipc: C12N 13/00 20060101ALI20110929BHEP

Ipc: A61K 33/00 20060101ALI20110929BHEP

Ipc: C12N 5/00 20060101AFI20110929BHEP

17Q First examination report despatched

Effective date: 20130527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160927